trending Market Intelligence /marketintelligence/en/news-insights/trending/SanR_p-bYCoxC0CNdJVsmA2 content esgSubNav
In This List

FIT Biotech, InnaVirVax collaborate on HIV treatment

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

Blog

Essential IR Insights Newsletter - February 2023

Blog

Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales


FIT Biotech, InnaVirVax collaborate on HIV treatment

FIT Biotech Oy is collaborating with InnaVirVax to develop an HIV treatment.

The companies will combine their proprietary immunotherapeutic HIV-vaccines to produce a drug candidate that will undergo phase 2 trial in 2017.

InnaVirVax will conduct and fund the clinical study in return for co-ownership of the immunotherapy. The companies will then seek additional third-party support and resources to further develop and commercialize the combination of the two products.